Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Branch

Ophthalmology Cedar Park, TX Medical Doctor

NPI 1417142977 CMS profile 199864

1130 Cottonwood Creek Trl Ste D4, Cedar Park, TX 78613

Open in the dashboard

General payments

$4,739

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Branch of Cedar Park, TX is reported in the CMS Open Payments database as having received $4,739 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,218 37
2024 General $497 12
2023 General $734 18
2022 General $452 15
2021 General $712 21
2020 General $256 10
2019 General $869 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Branch
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to John Branch were reported at $1,218. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year John Branch Ophthalmology median Middle half National median
2019 $869 $258 $104–$655 $163
2020 $256 $126 $45–$321 $114
2021 $712 $205 $76–$534 $132
2022 $452 $266 $100–$678 $149
2023 $734 $308 $117–$745 $160
2024 $497 $340 $127–$846 $164
2025 $1,218 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $1,470 28 payments
  2. Johnson & Johnson Surgical Vision, Inc. $1,422 45 payments
  3. RxSight Inc $1,050 32 payments
  4. TissueTech, Inc. $305 9 payments
  5. Carl Zeiss Meditec, Inc. $137 1 payment
  6. Mallinckrodt Enterprises LLC $119 1 payment
  7. Novartis Pharmaceuticals Corporation $95 1 payment
  8. Harrow Eye, LLC $42 2 payments
  9. Bausch & Lomb Americas Inc. $37 2 payments
  10. Ivantis, Inc $33 1 payment
  11. Other $29 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,488 122 payments
  2. Travel and Lodging $223 1 payment
  3. Honoraria $28 1 payment
Products named General payments · program years 2019–2025
  1. RXSIGHT LIGHT DELIVERY DEVICE (LDD) $1,036 31 payments
  2. RXSIGHT CONTACT LENS $1,036 31 payments
  3. RXSIGHT INJECTOR CARTRIDGE $1,036 31 payments
  4. RXSIGHT INJECTOR HANDPIECE $1,036 31 payments
  5. LIGHT ADJUSTABLE LENS (LAL) $1,018 30 payments
  6. VERITAS Vision System $518 19 payments
  7. Tecnis Simplicity $383 6 payments
  8. Tecnis IOL Optics $257 8 payments
  9. Tecnis IOL Optics $211 8 payments
  10. Tecnis IOL Optics $188 6 payments
  11. Other $2,564 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

485

Median for Ophthalmology: 891

Drug cost

$28,109

Median for Ophthalmology: $68,233

Branded share of claims

16.9%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 28 $14,753
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 22 $3,703
Latanoprost Generic 228 $2,957
Timolol Maleate Generic 67 $1,689
Prednisolone Acetate Generic 54 $1,595
Travoprost Generic 11 $1,483
Brimonidine Tartrate Generic 14 $853
Moxifloxacin Moxifloxacin Hcl Brand 32 $809
Diclofenac Sodium Generic 29 $268

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$226,300

Medicare's payments for the services billed

Medicare patients

486

Average age 75

Services billed

1,646

314 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 39%
Diabetes 27%
Ischemic heart disease 23%
Atrial fibrillation 16%
Depression 16%
Osteoporosis 16%
Chronic kidney disease 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record